Immunic, Inc. (NASDAQ:IMUX) Receives Average Rating of “Buy” from Analysts
Immunic, Inc. (NASDAQ:IMUX – Get Free Report) has earned a consensus recommendation of “Buy” from the eight research firms that are presently covering the stock, MarketBeat.com reports. Six research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 1-year price target among […]
Immunic, Inc. (NASDAQ:IMUX – Get Free Report) has earned a consensus recommendation of “Buy” from the eight research firms that are presently covering the stock, MarketBeat.com reports. Six research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 1-year price target among […]